Where does Amilyfe, LLC. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Amilyfe, LLC. ranks #38,762 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Amilyfe, LLC. hold?

Amilyfe, LLC. holds 6 US utility patents granted between 2024 and 2025, spanning 4 technology areas.

What is Amilyfe, LLC.'s Innovation Score?

Amilyfe, LLC. has an Innovation Score of 36.2 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Amilyfe, LLC.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Amilyfe, LLC..

What does claim depth mean for Amilyfe, LLC.'s patents?

Amilyfe, LLC.'s patents average 15.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Amilyfe, LLC. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Amilyfe, LLC.

Q: What technology areas does Amilyfe, LLC. focus on?

Amilyfe, LLC.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Amilyfe ranks #38,762 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#38,762
of 49,997 US assignees by volume: Top 47%
by Innovation Score (36.2/100): 15.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R38762 · US Corporation #38,762 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #38,762/49,997
PHOTO-FINISH American Medical
CPC-NARROW A61P · 4 areas
INNOV-THIN 36.2/100
CLAIMS-RICH 15.2 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2024–2025 · 2y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: American Medical Technologies, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Amilyfe · this assignee

36
3D Lighting… · lowest

7

What this shows Amilyfe's Innovation Score is 36.2/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Amilyfe's grants concentrate

Amilyfe, LLC. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). By volume, Amilyfe sits between American Medical Technologies, LLC and Amper Music, Inc..

Amilyfe's three-year grant acceleration

Amilyfe, LLC. shows 2 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

American Medical

6
American Muscle D…

6
American Security…

6
Amfag S r l

6
Amoena Medizin-or…

6
Ampac Fine Chemic…

6
Ampacet

6
Amper Music

6
Amilyfe ◀

6

What this shows Amilyfe holds 6 patents at rank #38,632, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Amilyfe

By rank, the assignees closest to #38,632 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Amilyfe's primary technology class.

Amilyfe's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table

Amilyfe, LLC. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2024	2	33.3%
2025partial year	4	66.7%

Which technologies does Amilyfe, LLC. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 2

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#38,762

of 49,997 tracked assignees

Innovation Score

36.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Amilyfe, LLC.'s patent record in context - here's where to go next.

Amilyfe, LLC.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #38,762 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Amilyfe, LLC. against American Medical Technologies, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.